uniQure Selloff on 48-Month AMT-130 Data: Tactical Long With Tight Thesis and Defined Risk

Hook & thesis

uniQure collapsed after the release of updated 48-month data for AMT-130, the company's Huntington's disease gene therapy candidate, sparking a dramatic one-day decline and fresh legal headlines on 09/29/2026. The selloff was large in magnitude and size: today's intraday range was $22.47 to $26.00 on volume of 25,888,108 shares - many multiples of the stock's average two-week volume (~1.6M). That sort of liquidation often creates tactical buying opportunities for disciplined traders.

I'm marginally bullish into the post-data stabilization window. This is a trade idea, not a long-term fundamental call. The setup rests on three pillars: (1) extreme technical oversold signals (RSI ~18), (2) heavy intraday volume that likely flushed weak hands and created a new base candidate, and (3) a balance sheet bolstered by a $225 million offering priced on 06/24/2026 that stretched the cash runway. Trade plan: enter $25.285, target $42.00, stop $18.50, mid term (45 trading days).

What uniQure does and why the market cares

uniQure N.V. develops and commercializes gene therapies, focused on severe and high-unmet-need indications such as hemophilia, Huntington's disease, refractory temporal lobe epilepsy, and Fabry disease. Gene therapy outcomes are binary and headline-driven: positive efficacy or regulatory alignment can re-rate a biotech rapidly, while disappointing readouts can wipe out multiples. That dynamic is why the market is hypersensitive to the AMT-130 48-month dataset and any subsequent interpretation by regulators and opinion leaders.

Concrete data that matters right now

• Share price: $25.285 (current); previous close was $39.11 before the selloff.
• Today's trading: open $23.85, high $26.00, low $22.47, volume 25,888,108 (vs. avg vol ~1.6M).
• Market cap (snapshot): ~$1.75B with ~69.37M shares outstanding and a float of ~64.46M.
• Short interest: ~9.92M shares (settlement 09/15/2026) - roughly 15% of the float and days-to-cover near 8.1 using recent volume.
• Technicals: 10/20/50-day SMAs in the low-to-mid $40s, EMA values similarly above current price; RSI ~18 indicating extreme oversold condition and MACD showing bearish momentum.
• Balance sheet action: uniQure priced an upsized public offering of ~4.95M ordinary shares at $45.50 on 06/24/2026, generating ~ $225M in gross proceeds.

Why this setup can work as a swing trade

Two forces are at work. First, the headline-driven selloff can overshoot as holders and algorithmic flows unwind. The intraday volume spike suggests a capitulation day that can be followed by a multi-week retracement as buyers step in. Second, the company executed a sizable equity raise in June 2026, which likely extended the runway and reduces immediate cash-driven existential risk. That combination - forced selling meets tangible liquidity - is the classic environment for a tactical long with defined risk.

Valuation framing

At $25 the market cap is roughly $1.75B. That valuation reflects more than the near-term commercial prospects; it prices in long-term optionality tied to AMT-130 and other pipeline programs. UniQure's price-to-book and price-to-sales ratios are elevated in public datasets, and the company has negative EPS and free cash flow profiles in the near term. The practical implication: upside will come from re-acceleration of narrative (readouts, improved analyses, regulatory clarity) rather than from tidy multiples compression. For a swing trade, I'm not valuing the franchise on DCF math - I'm trading the behavioral bounce and liquidity dynamics.

Catalysts to watch (near-term to mid-term)

• Management commentary and deeper subgroup analyses on the 48-month AMT-130 data - any sign that signals were concentrated in subpopulations could alter the narrative.
• Regulatory interaction updates. Given prior FDA disagreements and public scrutiny, any clarifying statement about study design or next steps would be market-moving.
• Legal developments. Several securities investigations and class action notices are in the news; resolution or consolidation of litigation headlines could remove a risk premium.
• Secondary flow: short-covering or technical mean reversion toward the 10-50 day averages if selling pressure abates, amplified by the high short interest (~9.92M shares).

Trade plan (actionable)

Rationale: Target $42 approximates the recent 50-day SMA neighborhood (~$44) and is a realistic technical rebound zone if selling pressure subsides. The stop at $18.50 limits downside and sits well below today's intraday low ($22.47) and significantly above the 52-week low ($8.73) - it is sized to protect capital against a drawn-out re-rating while giving the trade room to breathe through post-data volatility.

Position sizing & execution notes

This is a high-volatility biotech position. Use a small, defined allocation consistent with your risk appetite. Consider scaling in 50% at $25.285 and the remainder on a sub-$23 dip, or use a limit order near the entry to avoid price slippage in fast-moving markets. Monitor volume patterns and short-volume prints - elevated short-volume on consecutive days can create short-squeeze dynamics that amplify moves in either direction.

Risks & counterarguments

This trade carries material risks; lay them out and size accordingly.

• Regulatory risk: AMT-130's 48-month data disappointed expectations, and the FDA has a track record of demanding tight data alignment. Further regulatory skepticism or a formal rejection could produce another leg down.
• Legal & reputational risk: uniQure faces securities investigations and past class action activity related to prior communications and FDA interactions. Litigation headlines can impede recovery even if the underlying science is salvageable.
• Balance-sheet & dilution risk: while the company raised ~ $225M on 06/24/2026, ongoing R&D burn and further financing needs could introduce dilution that limits upside for existing shareholders.
• Binary science risk: Gene therapy outcomes are binary. Even if the market stabilizes short term, the long-term valuation depends on clinical and regulatory success that is far from guaranteed.
• Technical risk: Momentum indicators are bearish (MACD negative) and price is well below moving averages; further technical deterioration could make the stop necessary.

Counterargument to my thesis: One could argue this is a classic fade-the-rally short setup rather than a buy. The AMT-130 48-month data created legitimate questions about durability and effect size; absent convincing supportive subgroup analyses or regulator-friendly interpretations, buyers may be stepping into a value trap. Additionally, persistent negative sentiment and legal noise can keep the stock depressed regardless of short-term technical oversold conditions.

What would change my mind

I will abandon the bullish swing if any of the following occurs: (1) management issues guidance or commentary that materially weakens the case for AMT-130 durability, (2) a meaningful new financing at substantially lower prices that increases dilution risk and underscores funding stress, or (3) sustained negative regulatory commentary that indicates the program is unlikely to proceed on a path acceptable to investors. Conversely, if management releases constructive subgroup analyses or regulatory dialogue indicating clarity on trial design, I'll increase conviction and consider a position size increase.

Bottom line: This is a tactical, high-risk swing trade. The heavy volume capitulation and stretched technicals create a favorable asymmetry for a disciplined buyer with a tight stop and realistic target. Size the position small, respect the stop at $18.50, and watch for clarifying developments around the AMT-130 readout and legal/regulatory headlines.

Key dates to watch in the coming weeks

• 09/29/2026 - Day of the headline 48-month data release and subsequent selloff; expect follow-up analyst notes and management statements in the days that follow.
• 06/24/2026 - Offering priced; use that date as reference for the enlarged cash runway and dilution dynamics.

Trade responsibly. This is a speculative biotech position that requires active monitoring and strict risk controls.